Table 3.
Sociodemographic and clinical characteristics of patients in the DCE
| Characteristics | Overall (N = 200) |
|---|---|
| Age (years), mean (SD) | 53.78 (12.73) |
| Sex (male), n (%) | 106 (53) |
| Country, n (%) | |
| UK | 52 (26) |
| Spain | 53 (26) |
| France | 33 (16) |
| Germany | 62 (31) |
| Highest education level, n (%) | |
| No formal qualifications | 27 (14) |
| Secondary education | 89 (44) |
| Higher education | 53 (26) |
| Postgraduate degree | 31 (16) |
| Time since diagnosis of CKD (years), mean (SD) | 6.02 (7.49) |
| Time since diagnosis of anaemia of CKD (years), mean (SD) | 3.45 (3.44) |
| Receive iron supplements on a regular basisa, n (%) | |
| Oral iron supplements | 145 (72) |
| Intravenous iron supplements | 25 (12) |
| No iron supplements | 34 (17) |
| Current erythropoiesis-stimulating agent treatment, n (%) | |
| Erythropoietin | 122 (61) |
| Epoetin alfa | 18 (9) |
| Epoetin beta | 29 (14) |
| Darbepoetin alfa | 40 (20) |
| Methoxy polyethylene glycol-epoetin beta | 14 (7) |
| Frequency of erythropoiesis-stimulating agent, n (%) | |
| Three times per week | 10 (5) |
| Twice per week | 45 (22) |
| Once per week | 62 (31) |
| Once every 2 weeks | 52 (26) |
| Once every month | 29 (14) |
| Otherb | 2 (1) |
| Administration of erythropoiesis-stimulating agent, n (%) | |
| Intravenous | 37 (18) |
| Subcutaneous | 163 (82) |
| Regular use of an injectable medicine for other health problems, n (%) | |
| Yes | 54 (27) |
| No | 146 (73) |
CKD chronic kidney disease, DCE discrete choice experiment, SD standard deviation
aOral iron and intravenous iron were not mutually exclusive. No iron could not be selected in addition to oral or intravenous iron
bOnce every 3 weeks and every 6 months